In-vitro experiments with colon cancer cells that have a different level of COXs expression show that NSAIDs (e.g. sulindac sulfone) can up-regulate 15-LOX-1 expression and increase the formation of 13-S-HODE—the main metabolic product of this enzyme. Here, OLR1 is linked to colonic neoplasm.